Chamaraux-Tran, Thien-Nga; Muller, Marie; Pottecher, Julien; Diemunsch, Pierre A.; Tomasetto, Catherine; Namer, Izzie-Jacques; Dali-Youcef, Nassim published the artcile< Metabolomic impact of lidocaine on a triple negative breast cancer cell line>, SDS of cas: 112-63-0, the main research area is lidocaine human triple neg breast cancer cell metabolomics; anesthesia; cancer progression; cancer surgery; lidocaine; metabolomics; onco-anesthesia; perioperative period.
Metabolomics and onco-anesthesia are two emerging research fields in oncol. Metabolomics (metabolites anal.) is a new diagnostic and prognostic tool that can also be used for predicting the therapeutic or toxic responses to anticancer treatments. Onco-anesthesia studies assess the impact of anesthesia on disease-free and overall survival after cancer surgery. It has been shown that local anesthetics (LA), particularly lidocaine (LIDO), exert antitumor properties both in vitro and in vivo and may alter the biol. fingerprints of cancer cells. As LA are known to impair mitochondrial bioenergetics and byproducts, the aim of the present study was to assess the impact of LIDO on metabolomic profile of a breast cancer cell line. Breast cancer MDA-MB-231 cells were exposed for 4 h to 0.5 mM LIDO or vehicle (n = 4). The metabolomic fingerprint was characterized by high resolution magic angle spinning NMR spectroscopy (HRMAS). The multivariate technique using the Algorithm to Determine Expected Metabolite Level Alteration (ADEMA) (Cicek et al., PLoS Comput. Biol., 2013, 9, e1002859), based on mutual information to identify expected metabolite level changes with respect to a specific condition, was used to determine the metabolites variations caused by LIDO. LIDO modulates cell metabolites levels. Several pathways, including glutaminolysis, choline, phosphocholine and total choline syntheses were significantly downregulated in the LIDO group. This is the first study assessing the impact of LIDO on metabolomic fingerprint of breast cancer cells. Among pathways downregulated by LIDO, many metabolites are reported to be associated with adverse prognosis when present at a high titer in breast cancer patients. These results fit with the antitumor properties of LIDO and suggest its impact on metabolomics profile of cancer cells. These effects of LIDO are of clin. significance because it is widely used for local anesthesia with cutaneous infiltration during percutaneous tumor biopsy. Future in vitro and preclin. studies are necessary to assess whether metabolomics anal. requires modification of local anesthetic techniques during tumor biopsy.
Frontiers in Pharmacology published new progress about Anesthesia. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, SDS of cas: 112-63-0.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics